It seems that the now infamous Bridgemark Group might be getting the gang back together after all. The group, notorious for using an exemption intended for consultants to effectively dump their shares on retail investors while enabling public issuers to be able to claim that they had fully subscribed private placements, seems to have infiltrated … Continue reading RavenQuest BioMed: The Next Bridgemark Group Target?